Hi Greenwave - I have wondered the same thing re both impact and cost.
My conclusion is that assuming it works, the cost of treatment will be considered low if it helps people regain their lives and in doing so, they are able to take care of themselves moving forward meaning there is less reliance on other government funded programs.
If the government pays 25k to fund the treatment and to get someone back up and running and able to work and take care of themselves financially then that is going to look like a good investment.
I know this perspective only focuses on the economic equation but it helps resolve the value proposition of what Clarion is offering, and explains why the government is heavily incentivized to contribute to the cost of treatment.
As for impact on NASDAQ and US share holders, I am hoping it pales in comparison compared to the value of our other programs - although for any small biotech, having a revenue stream has to be looked upon favorably.
Good luck GW.
R
IHL Price at posting:
4.1¢ Sentiment: Buy Disclosure: Held
